Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: A pilot study

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 742-748

  Monteiro, Polyana ^a   Perez, Iñaki ^a   Laguno, Montserrat ^a   Martínez rebollar, Maria ^a   González cordon, Ana ^a   Lonca, Montserrat ^a   Mallolas, Josep ^a   Blanco, Jose L ^a   Gatell, Jose M ^a   Martínez, Esteban ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antiretroviral therapy efficacy; Dual antiretroviral therapy; PI NRTI sparing regimen

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ETRAVIRINE; PYRIDAZINE DERIVATIVE; RALTEGRAVIR;

ADVERSE DRUG REACTION; COHORT ANALYSIS; FEMALE; HIV INFECTIONS; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIDAZINES; PYRROLIDINONES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84890290596     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt406     Document Type: Article

References (27)

1. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338: a3172.
2. Marzolini C, Elzi L, Gibbons S et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010; 15: 413-23.
3. Worm SW, Sabin C,Weber R et al. Risk ofmyocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-30.
4. Ryom L, Mocroft A, Kirk O et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013; 207: 1359-69.
5. Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-54.
6. Katlama C, Clotet B, Mills A et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010; 15: 1045-52.
7. Costagliola D, Ledergerber B, Torti C et al. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis 2012; 12: 119-27.
8. Guaraldi G, Orlando G, Zona S et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53: 1120-6.
9. Eron JJ, Young B, Cooper DA et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396-407.
10. Marti{dotless}́nez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24: 1697-707.
11. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42: 1608-18.
12. Poirier JM, Robidou P, Jaillon P. Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867: 277-81.
13. Casado JL, de Los Santos I, Del Palacio M et al. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART. HIV Clin Trials 2013; 14: 1-9.
14. Calin R, Paris L, Simon A et al. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy. Antivir Ther 2012; 17: 1601-4.
15. Vingerhoets J, Tambuyzer L, Azijn H et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24: 503-14.
16. Vingerhoets J, Azijn H, Fransen E et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79: 12773-82.
17. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
18. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
19. Tambuyzer L, Vingerhoets J, Azijn H et al. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res Hum Retroviruses 2010; 26: 1197-205.
20. Bannister WP, Ruiz L, Cozzi-Lepri A et al. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS 2008; 22: 367-76.
21. Anderson MS, Kakuda TN, Hanley W et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008; 52: 4228-32.
22. Ménard A, Solas C, Mokthari S et al. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases. AIDS 2009; 23: 869-71.
23. Do VT, Higginson RT, Fulco PP. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine. Am J Health Syst Pharm 2011; 68: 2049-54.
24. Sandkovsky U, Swindells S, Moore R et al. Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection. Pharmacotherapy 2012; 32: 142-7.
25. Sainz T, Serrano-Villar S, Di{dotless}́az Let al. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS 2013; 27: 1513-6.
26. Serrano-Villar S, Gutiérrez C, Vallejo A et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect 2013; 61: 57-66.
27. Varghese V, Shahriar R, Rhee SY et al. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2009; 52: 309-15.